US judge says no stay for Apotex as BMS, Sanofi enter final damages phase in Plavix case
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Sanofi-Aventis can now pursue economic damages from Apotex for the firm's brief launch of an infringing generic version of the blockbuster drug, Plavix (clopidogrel), in 2006, a federal judge has ruled.